Asia Pacific Liver Fibrosis Treatment Market
市场规模（十亿美元）
CAGR :
% 
USD
3.77 Billion
USD
9.93 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 3.77 Billion |
 Market Size (Forecast Year) |
USD 9.93 Billion |
 CAGR |
% |
| Major Markets Players |
亞太肝纖維化治療市場，按治療類型（藥物和手術/療法）、分期（F2、F1、F3 和 F4）、適應症（非酒精性脂肪性肝炎 (NASH)、乙肝和丙肝誘發的纖維化、酒精性肝病 (ALD)、自體免疫性肝病、遺傳性疾病等）、性別（男性和女性門診、零售產業趨勢與預測（至 2032 年）
亞太肝纖維化治療市場規模
- 2024 年亞太地區 肝纖維化治療市值為37.7 億美元，預計到 2032 年將達到 99.3 億美元
- 在 2025 年至 2032 年的預測期內，市場可能以12.9% 的複合年增長率成長，主要原因是消費者對自然健康解決方案的認識不斷提高
- 這種增長是由肝病盛行率不斷上升等因素所推動的。此外，價格承受能力也推動了酒精消費量的上升。
亞太肝纖維化治療市場分析
- 肝病數量的不斷增加使得需要有效治療方案的患者群體不斷擴大，尤其是B型肝炎和C肝等疾病。酒精消費量增加、不健康的飲食習慣以及肥胖率上升等因素都導致越來越多的人被診斷出患有這些肝病
- 隨著肝損傷的加重，肝纖維化的風險也會增加，這給醫療保健系統提供有效治療方案帶來了沉重的負擔。這種不斷增長的需求推動了標靶療法的開發和普及，推動了市場成長，因為醫療保健提供者正在尋求管理這種疾病的創新解決方案
- 此外，醫療保健從業人員和公眾意識的提高使得更多的人在肝病早期階段得到篩檢和診斷。診斷技術的進步，包括非侵入性影像和血液測試，使得在疾病進展過程中能夠更早發現肝纖維化。這種早期檢測可以及時幹預，刺激對有效逆轉或控制肝纖維化的創新治療的需求
- 例如，2023年8月，根據NCBI發表的一篇文章，肝病每年導致200萬人死亡，佔所有死亡人數的4%（全球每25人死亡中就有1人死於肝病）；大約三分之二的肝臟相關死亡發生在男性身上。這項令人震驚的統計數據凸顯了對有效治療方案的迫切需求，並凸顯了肝病帶來的沉重公共衛生負擔，進一步促使醫療保健系統和製藥公司優先開發專門針對肝纖維化及其根本原因的創新療法
- 因此，製藥公司和醫學研究人員被迫投資開發新的治療方案，從而推動市場發展，因為利害關係人的目標是對抗肝病及其相關併發症的發生率上升。
報告範圍和亞太肝纖維化治療市場細分
|
屬性 |
全球肝纖維化治療市場關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
亞太肝纖維化治療市場趨勢
“肝病盛行率不斷上升”
- 肝病盛行率的不斷上升正成為一個重要的全球健康議題，大大增加了全球醫療負擔
- 過量飲酒、肥胖率上升、病毒性肝炎感染以及不健康的生活方式等因素導致脂肪肝、肝硬化和肝癌等疾病的發生率激增
- 非酒精性脂肪肝（NAFLD）的發生率不斷上升，特別是與糖尿病和代謝症候群相關的發生率也令人擔憂。因此，對早期診斷、有效治療方案和公共衛生措施的需求日益增加。預計這一趨勢將推動肝病治療市場的創新和成長
亞太肝纖維化治療市場動態
驅動程式
“酒精消費量上升”
- 酒精消費量的增加是全球肝纖維化治療市場的重要因素，因為它與肝病的發生率直接相關，尤其是酒精性肝病（ALD）
- 隨著越來越多的人定期大量飲酒，罹患肝臟相關併發症（包括肝纖維化和肝硬化）的風險顯著增加
- 慢性酒精中毒會導致發炎、脂肪堆積，最終導致肝臟纖維化，因為肝臟會反覆受到損傷和修復
- 酒精相關肝病的盛行率日益上升，迫切需要有效的治療和管理策略來幫助減輕肝損傷並改善患者的預後。
例如，
- 2024 年 10 月，根據《國際精神衛生系統期刊》發表的一篇文章，酒精消費的盛行率在基線和追蹤中分別為 54.5% 和 47.7%。此外，12%的男性表示剛開始喝酒。酒精消費的普遍性導致全球肝纖維化發生率上升，可能影響市場成長
- 2024 年 6 月，根據 STAT 的數據，與酒精有關的死亡人數呈上升趨勢，專家尤其擔心年輕人和女性的死亡人數會增加。 2019 年至 2020 年間，美國與酒精相關的死亡人數激增 25.5%，佔所有死亡人數的 3%。此外，酒精相關死亡人數增加最多的是25至34歲和35至44歲的人群，這兩個群體的死亡人數都增加了37%以上
- 此外，社會對酒精消費的接受度和正常化程度不斷提高，尤其是在年輕人群體中，進一步加劇了這個問題，導致更多人面臨肝纖維化的風險
- 這一趨勢促進了肝纖維化治療市場的成長，並強調了旨在減少酒精消費和預防肝病的公共衛生舉措的重要性
機會
“肝纖維化管理的新興技術和先進治療方法”
-
基因治療、標靶分子治療和生物製劑等新興技術正在改變治療格局
-
最近的創新集中在專門針對纖維化進展途徑的藥物，例如 FXR 激動劑、TGF-β 抑制劑和抗發炎劑。此外，彈性成像等非侵入性診斷工具正在改善早期檢測
-
這些進步為 NASH（非酒精性脂肪性肝炎）和肝硬化等疾病提供了更有效、個人化的治療，從而改善了患者的治療效果
-
2024年2月，Springer Nature發表了一篇文章，文章回顧了診斷和抑制肝纖維化的新興方法。進展包括非侵入性生物標記、影像技術和間質幹細胞等細胞療法。吡非尼酮和奧貝膽酸等有前景的抗纖維化藥物，以及組織工程、奈米技術和微流體模型的創新，展現出個人化、精準治療的潛力
-
NCBI 2021 年 9 月的一篇文章強調，肝纖維化治療的新興技術專注於針對肝星狀細胞活化等分子途徑的先進療法。基因治療、生物製劑、小分子抑制劑和非侵入性診斷等創新改善了早期檢測和治療。幹細胞療法和組織工程也為逆轉纖維化和促進康復提供了希望
-
隨著治療策略和診斷技術的不斷發展，肝纖維化治療正在迅速發展
-
這些創新為更好地管理肝病帶來了希望，確保患者能夠獲得更有效、個人化、副作用更少的治療，最終改善全球健康狀況
限制/挑戰
“對肝病的認識有限”
- 對肝臟疾病的認識有限，阻礙了早期診斷和適當的干預。許多人仍然沒有意識到與肝臟疾病相關的風險因素和症狀，常常將模糊的疾病跡象歸咎於其他不太嚴重的問題
- 缺乏知識會延遲醫療諮詢，直到疾病發展到晚期階段，例如肝纖維化或肝硬化，此時治療方案變得更加複雜且效果更差
- 因此，晚期診斷降低了成功治療的可能性，並透過限制尋求及時治療的患者數量來限制整體市場的成長
例如，
- 2024年4月，魯賓表示，患者直到疾病發展到關鍵階段才意識到自己的病情，這迫切需要重新評估肝臟健康意識、檢測和管理的方法。然而，肝臟健康管理的一個重大障礙是對肝臟疾病及其相關風險因素的了解有限
- 2021 年 7 月，根據一項涉及五項全國健康和營養檢查調查中的 11,700 名成年人（18 歲以上）的研究，美國近 96% 的 NAFLD 成年人不知道自己患有肝病，尤其是年輕人。因此，提高對肝臟健康的認識和教育對於改善患者預後、促進更積極主動的肝纖維化管理和治療市場擴張至關重要
- 2021年1月，Springer Nature通報，在研究論文《2型糖尿病患者缺乏對肝臟器官損害的認識》中進行的研究分析中，納入的825名患者中，8.1%（95% CI 5.1%-12.7%）的脂肪變性患者知道自己患有肝臟疾病。此外，在美國具有全國代表性的 2 型糖尿病成年人樣本中，晚期肝纖維化的盛行率很高。不到 20% 的晚期纖維化患者意識到自己患有肝臟疾病
- 認知不足會阻礙患者的潛在治療效果，並透過減少早期參與醫療服務的人數來抑制市場成長
- 因此，提高對肝臟健康的認識和教育對於改善早期診斷、提高治療效果以及最終促進更強的肝纖維化治療市場至關重要
全球肝纖維化治療市場範圍
市場根據產品類型、治療方法、來源基礎、應用、給藥途徑、購買方式、年齡層、性別、最終用戶和分銷管道進行細分。
|
分割 |
細分 |
|
按治療類型 |
|
|
按階段 |
|
|
按適應症 |
|
|
按最終用戶 |
|
|
按分銷管道 |
|
亞太肝纖維化治療市場區域分析
“中國是大型主機市場的主導地區”
- 中國引領亞太地區肝纖維化治療市場，得益於其強大的醫療基礎設施、肝臟相關疾病的高發性以及對早期診斷和乾預策略的高度重視
- 該國受益於廣泛的醫療保健覆蓋、完善的報銷政策以及對非侵入性診斷和治療方案日益增長的需求
- 中國在臨床研究方面的領導地位以及在肝病宣傳運動中的積極參與進一步支持了市場的成長
- 先進療法的日益普及、患者意識的不斷提高以及政府應對慢性肝病的舉措，促成了德國在該地區佔據主導地位
“中國預計將實現最高成長率”
- 中國也是成長最快的市場，推動力包括纖維化生物標記的持續創新、製藥公司加大研發投入以及酒精相關和非酒精性脂肪肝疾病發生率的上升。
- 這些因素共同使中國成為亞太地區肝纖維化治療的中心樞紐，並使其成為該地區最大且成長最快的市場。
亞太肝纖維化治療市佔率
市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、亞太地區業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。
市場中主要的市場領導者有：
- F. Hoffmann-La Roche Ltd（瑞士）
- 雅培（美國）
- 拉雷農醫療保健私人有限公司有限公司（印度）
- GENFIT SA（法國）
- Madrigal Pharmaceuticals（美國）
- Aligos Therapeutics（美國）
- 輝瑞公司（美國）
- Enanta Pharmaceuticals, Inc.（美國）
- 百時美施貴寶公司（美國）
- Vertex Pharmaceuticals Incorporated（美國）
- 武田藥品工業株式會社（日本）
- Hepion Pharmaceuticals（美國）
- Echosens（法國）
- Galectin Therapeutics, Inc.（美國）
- Conatus Pharmaceuticals（美國）
- Tvardi Therapeutics（美國）
- Viking Therapeutics（美國）
- Calliditas Therapeutics AB（瑞典）
- Novomedix（美國）
- Galecto Biotech（丹麥）
- Pilant Therapeutics, Inc.（美國）
- Sagimet Biosciences（美國）
- Gyre Therapeutics, Inc.（美國）
- Akero Therapeutics, Inc.（美國）
- CureVac SE（德國）
- 諾和諾德公司（丹麥）
- 益普生製藥（法國）
- AdAlta有限公司（澳洲）
- Alentis Therapeutics AG（瑞士）
- 吉利德科學公司（美國）
- 艾伯維公司（美國）
- 默克公司（美國）
- 諾華公司（瑞士）
- Intercept Pharmaceuticals, Inc.（美國）
亞太肝纖維化治療市場最新發展
- 2024年6月，吉利德科學在米蘭舉行的2024年歐洲肝病研究協會（EASL）大會上展示了這項新研究，重點關注原發性膽汁性膽管炎（PBC）、B型肝炎（HBV）、丁型肝炎病毒（HDV）等肝病。主要演講將包括 ASSURE 研究 seladelpar 治療 PBC 的長期數據、替諾福韋用於預防 HBV 肝癌的結果，以及 MYR204 和 MYR301 研究 Hepcludex 治療 HDV 的發現。這項研究凸顯了吉利德致力於推進肝病治療方案的承諾
- 2024 年 10 月，Intercept Pharmaceuticals, Inc 討論了他們為探索原發性膽汁性膽管炎 (PBC) 護理中的種族差異和差距而做出的持續努力。該公司正在解決不同人群在 PBC 的診斷、治療和管理方面可能面臨的不同挑戰。透過探索這些差異，Intercept 旨在改善所有患者獲得護理和治療結果的機會，從而可能減少有效治療肝病（包括纖維化）的障礙
- 2022年11月，美國食品藥物管理局（FDA）批准Vemlidy（替諾福韋艾拉酚胺）用於治療12歲及以上患有代償性肝病的兒科患者的慢性乙型肝炎病毒（HBV）感染。此次批准擴大了 Vemlidy 的使用範圍，該藥物最初於 2016 年獲批用於治療患有慢性乙型肝炎的成年人。這項批准基於一項 2 期臨床試驗，該試驗證明了 Vemlidy 對這群年輕患者的有效性和安全性
- 2022年9月，吉利德科學完成了英國生技公司MiroBio的收購，該公司專注於透過針對免疫抑制受體的激動劑來恢復免疫平衡。此次收購價值約 4.05 億美元，為吉利德提供了 MiroBio 的發現平台及其免疫抑制受體激動劑產品組合。 MiroBio 的主要研究抗體 MB272 針對免疫細胞來抑制發炎免疫反應，目前正處於第一階段臨床試驗階段。這項收購增強了吉利德在治療慢性免疫介導疾病方面的努力
- 2021年3月，吉利德科學與諾和諾德啟動2b期臨床試驗，擴大在非酒精性脂肪性肝炎（NASH）治療的合作。該研究調查了諾和諾德公司的 GLP-1 受體激動劑 semaglutide 與吉利德的 cilofexor（一種 FXR 激動劑）和 firsocostat（一種 ACC 抑制劑）聯合治療 NASH 導致的肝硬化患者的安全性和有效性。該試驗將評估這些療法對肝纖維化和 NASH 消退的影響，預計將於 2021 年下半年開始招募
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY
4.3 EPIDEMIOLOGY
4.3.1 INCIDENCE OF ALL BY GENDER
4.3.2 TREATMENT RATE
4.3.3 TREATMENT RATE
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.3.5 PATIENT TREATMENT SUCCESS RATES
4.4 MARKETED DRUG ANALYSIS
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.5.1 PATIENT FLOW DIAGRAM
4.5.2 KEY PRICING STRATEGIES
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES
5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES
6.1.2 RISING CONSUMPTION OF ALCOHOL
6.1.3 RISING LIVER TRANSPLANTATION RATES
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF LIVER DISEASES
6.2.2 REGULATORY CHALLENGES
6.3 OPPORTUNITIES
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS
6.4 CHALLENGES
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE
7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 ANTIVIRAL AGENTS
7.2.1.1 VELPATASVIR/SOFOSBUVIR
7.2.1.2 TENOFOVIR
7.2.1.3 LEDIPASVIR/SOFOSBUVIR
7.2.1.4 SOFOSBUVIR
7.2.1.5 ENTECAVIR
7.2.2 ANTIFIBROTIC AGENTS
7.2.2.1 OBETICHOLIC ACID
7.2.2.2 TGF-Β INHIBITORS
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS
7.2.2.5 OTHERS
7.2.3 ANTI-INFLAMMATORY DRUGS
7.2.3.1 CORTICOSTEROIDS
7.2.3.1.1 PREDNISONE
7.2.3.1.2 DEXAMETHASONE
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS
7.2.3.2.1 INFLIXIMAB
7.2.3.2.2 ETANERCEPT
7.2.3.3 INTERLEUKIN (IL) INHIBITORS
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)
7.2.4 IMMUNOSUPPRESSANTS
7.2.4.1 MYCOPHENOLATE MOFETIL
7.2.4.2 TACROLIMUS
7.2.4.3 CYCLOSPORINE
7.2.5 MARKETED DRUGS
7.2.5.1 VELPATASVIR/SOFOSBUVIR
7.2.5.2 TENOFOVIR
7.2.5.3 LEDIPASVIR/SOFOSBUVIR
7.2.5.4 OBETICHOLIC ACID (OCA)
7.2.5.5 SOFOSBUVIR
7.2.5.6 PIRFENIDONE
7.2.5.7 OTHERS
7.2.6 PIPELINE DRUGS
7.2.7 BRANDED DRUGS
7.2.7.1 EPCLUSA
7.2.7.2 VIREAD AND VEMLIDY
7.2.7.3 OCALIVA
7.2.7.4 HARVONI
7.2.7.5 SOVALDI
7.2.7.6 BARACLUDE
7.2.7.7 ACTOS
7.2.7.8 OTHERS
7.2.8 GENERIC DRUGS
7.2.9 ORAL
7.2.10 PARENTERAL
7.2.11 OTHERS
7.3 SURGERY/THERAPY
7.3.1 LIVER TRANSPLANTATION
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)
7.3.4 SPLIT LIVER TRANSPLANTATION
7.3.5 DOMINO LIVER TRANSPLANT
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)
7.3.6.3 LIVER ABLATION PROCEDURES
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)
7.3.6.3.2 MICROWAVE ABLATION (MWA)
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)
7.3.7.1 SEGMENTAL RESECTION
7.3.7.2 LOBECTOMY
7.3.7.3 WEDGE RESECTION
7.3.8 CELL-BASED THERAPY
7.3.8.1 STEM CELL THERAPY
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)
7.3.8.2 GENE THERAPY
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS
7.3.8.2.3 SIRNA-BASED THERAPIES
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS
7.3.8.2.4.2 EMRICASAN
7.3.8.2.4.3 PENTOXIFYLLINE
7.3.8.2.4.4 LOSARTAN
7.3.8.2.4.5 METHYL FERULIC ACID
7.3.8.2.4.6 OTHERS
7.4 OTHERS
8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES
8.1 OVERVIEW
8.2 F2
8.3 F1
8.4 F3
8.5 F4
9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION
9.1 OVERVIEW
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)
9.3 HEPATITIS B & C-INDUCED FIBROSIS
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS
9.4 ALCOHOLIC LIVER DISEASE (ALD)
9.5 AUTOIMMUNE LIVER DISEASES
9.5.1 AUTOIMMUNE HEPATITIS (AIH)
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)
9.6 GENETIC DISORDERS
9.6.1 HEMOCHROMATOSIS
9.6.2 WILSON’S DISEASE
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY
9.7 OTHERS
10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER
10.1 OVERVIEW
10.2 MALE
10.2.1 40-55 YEARS
10.2.2 ABOVE 55 YEARS
10.2.3 BELOW 40 YEARS
10.3 FEMALE
10.3.1 ABOVE 55 YEARS
10.3.2 40-55 YEARS
10.3.3 BELOW 40 YEARS
11 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC HOSPITALS
11.2.2 PRIVATE HOSPITALS
11.3 SPECIALTY CLINICS
11.3.1 HEPATOLOGY CLINICS
11.3.2 GASTROENTEROLOGY CLINICS
11.4 CLINICS
11.5 AMBULATORY AND RESEARCH CENTERS
11.6 OTHERS
12 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.2.1 RETAIL SALES
12.2.1.1 HOSPITAL PHARMACY
12.2.1.2 RETAIL PHARMACY
12.2.1.3 ONLINE PHARMACY
13 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY REGION
13.1 OVERVIEW
13.2 ASIA-PACIFIC
13.2.1 CHINA
13.2.2 JAPAN
13.2.3 INDIA
13.2.4 SOUTH KOREA
13.2.5 AUSTRALIA
13.2.6 SINGAPORE
13.2.7 THAILAND
13.2.8 INDONESIA
13.2.9 MALAYSIA
13.2.10 TAIWAN
13.2.11 NEW ZEALAND
13.2.12 PHILIPPINES
13.2.13 VIETNAM
13.2.14 REST OF ASIA-PACIFIC
14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 GILEAD SCIENCES, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT/NEWS
16.2 ABBVIE, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 MERCK & CO, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 NOVARTIS AG
16.4.1 COMPANY SNAPSHOTS
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 PIPELINE PRODUCT PORTFOLIO
16.4.6 RECENT DEVELOPMENT
16.5 INTERCEPT PHARMACEUTICALS, INC.
16.5.1 COMPANY SNAPSHOTS
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 PIPELINE PRODUCT PORTFOLIO
16.5.6 RECENT NEWS
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 1.1.5 RECENT DEVELOPMENT
16.7 ALIGOS THERAPEUTICS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 ALNICHE LIFE SCIENCES PVT. LTD.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ALENTIS THERAPEUTICS AG
16.9.1 COMPANY SNAPSHOT
16.9.2 PIPELINE PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 ADALTA LIMITED
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PIPELINE PRODUCT PORTFOLIO
16.10.4 RECENT NEWS
16.11 AKERO THERAPEUTICS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PIPELINE PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 BRISTOL-MYERS SQUIBB
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CALLIDITAS THERAPEUTICS AB
16.13.1 COMPANY SNAPSHOT
16.13.2 PIPELINE PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 CUREVAC SE
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 CONATUSPHARMA
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT/NEWS
16.16 ENANTA PHARMACEUTICALS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 ECHOSENS
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT/NEWS
16.18 F. HOFFMANN-LA ROCHE LTD
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 COMPANY SHARE ANALYSIS
16.18.4 PRODUCT PORTFOLIO
16.18.5 RECENT DEVELOPMENT
16.19 GALECTO BIOTECH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PIPELINE PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT/NEWS
16.2 GALECTIN THERAPEUTICS, INC.
16.20.1 COMPANY SNAPSHOTS
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS
16.20.3 PIPELINE PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 GYRE THERAPEUTICS, INC.
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT/NEWS
16.22 GENFIT SA
16.22.1 COMPANY SNAPSHOTS
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.22.3 PIPELINE PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 HEPION PHARMACEUTICALS
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PIPELINE PORTFOLIO
16.23.4 RECENT DEVELOPMENT
16.24 IPSEN PHARMA
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PIPELINE PRODUCT PORTFOLIO
16.24.4 RECENT NEWS/DEVELOPMENTS
16.25 LA RENON HEALTHCARE PVT. LTD.
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
16.26 MADRIGAL PHARMACEUTICALS
16.26.1 COMPANY SNAPSHOTS
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENT
16.27 NOVO NORDISK A/S
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PIPELINE PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENT
16.28 NOVOMEDIX
16.28.1 COMPANY SNAPSHOT
16.28.2 PIPELINE PRODUCT PORTFOLIO
16.28.3 RECENT DEVELOPMENT
16.29 PILANT THERAPEUTICS, INC.
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PIPELINE PRODUCT PORTFOLIO
16.29.4 RECENT NEWS
16.3 PFIZER INC.
16.30.1 COMPANY SNAPSHOT
16.30.2 REVENUE ANALYSIS
16.30.3 PIPELINE PRODUCT PORTFOLIO
16.30.4 RECENT DEVELOPMENT/NEWS
16.31 SAGIMET BIOSCIENCES
16.31.1 COMPANY SNAPSHOTS
16.31.2 REVENUE ANALYSIS
16.31.3 1.1.4 PRODUCT PORTFOLIO
16.31.4 RECENT DEVELOPMENT/NEWS
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.32.1 COMPANY SNAPSHOT
16.32.2 REVENUE ANALYSIS
16.32.3 PIPELINE PRODUCT PORTFOLIO
16.32.4 PRODUCT PORTFOLIO
16.32.5 RECENT DEVELOPMENT
16.33 TVARDI THERAPEUTICS
16.33.1 COMPANY SNAPSHOT
16.33.2 PIPELINE PRODUCT PORTFOLIO
16.33.3 RECENT DEVELOPMENT/NEWS
16.34 VERTEX PHARMACEUTICALS INCORPORATED
16.34.1 COMPANY SNAPSHOT
16.34.2 REVENUE ANALYSIS
16.34.3 PRODUCT PORTFOLIO
16.34.4 RECENT DEVELOPMENT
16.35 VIKING THERAPEUTICS
16.35.1 COMPANY SNAPSHOT
16.35.2 REVENUE ANALYSIS
16.35.3 PIPELINE PRODUCT PORTFOLIO
16.35.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 ASIA-PACIFIC INCIDENCE OF CIRRHOSIS BY GENDER (2019)
TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS
TABLE 3 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 7 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 9 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 10 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 12 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 13 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 16 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 17 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 19 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 20 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 22 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 23 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 24 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 26 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 27 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 ASIA-PACIFIC DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 75 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 78 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 80 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 81 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 83 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 84 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 86 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 88 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 89 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 91 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 92 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 94 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 95 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 97 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 98 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 99 ASIA-PACIFIC MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 ASIA-PACIFIC BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 103 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 ASIA-PACIFIC LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 ASIA-PACIFIC ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 ASIA-PACIFIC LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 ASIA-PACIFIC PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 ASIA-PACIFIC CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 ASIA-PACIFIC STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 ASIA-PACIFIC GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 ASIA-PACIFIC HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 113 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 114 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 118 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 121 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 CHINA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 128 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 130 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 131 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 133 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 134 CHINA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 CHINA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 136 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 138 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 139 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 141 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 142 CHINA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 CHINA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 144 CHINA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 145 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 147 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 148 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 149 CHINA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 CHINA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 153 CHINA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 CHINA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 CHINA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 CHINA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 CHINA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 CHINA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 CHINA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 CHINA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 CHINA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 CHINA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 163 CHINA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 164 CHINA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 CHINA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 CHINA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 CHINA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 168 CHINA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 CHINA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 CHINA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 171 CHINA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 CHINA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 CHINA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 CHINA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 178 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 180 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 181 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 183 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 184 JAPAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 JAPAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 186 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 188 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 189 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 191 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 192 JAPAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 JAPAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 194 JAPAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 195 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 197 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 198 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 199 JAPAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 JAPAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 203 JAPAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 JAPAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 JAPAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 JAPAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 JAPAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 JAPAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 JAPAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 JAPAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 JAPAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 213 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 214 JAPAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 JAPAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 JAPAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 218 JAPAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 JAPAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 221 JAPAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 JAPAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 224 JAPAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 INDIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 228 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 230 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 231 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 233 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 234 INDIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 235 INDIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 236 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 238 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 239 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 241 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 242 INDIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 INDIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 244 INDIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 245 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 247 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 248 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 249 INDIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 INDIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 253 INDIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 INDIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 INDIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 INDIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 INDIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 INDIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 INDIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 INDIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 INDIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 INDIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 263 INDIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 264 INDIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 INDIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 INDIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 INDIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 268 INDIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 INDIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 INDIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 271 INDIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 INDIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 INDIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 274 INDIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 278 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 280 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 281 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 283 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 284 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 286 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 288 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 289 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 291 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 292 SOUTH KOREA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 SOUTH KOREA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 294 SOUTH KOREA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 295 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 297 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 298 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 299 SOUTH KOREA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 SOUTH KOREA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 SOUTH KOREA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 SOUTH KOREA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 SOUTH KOREA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 SOUTH KOREA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 SOUTH KOREA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 SOUTH KOREA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 SOUTH KOREA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 SOUTH KOREA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 SOUTH KOREA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 313 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 314 SOUTH KOREA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 SOUTH KOREA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 SOUTH KOREA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 318 SOUTH KOREA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 SOUTH KOREA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 321 SOUTH KOREA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 SOUTH KOREA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 324 SOUTH KOREA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 328 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 330 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 331 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 333 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 334 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 336 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 338 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 339 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 341 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 342 AUSTRALIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 AUSTRALIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 344 AUSTRALIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 345 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 347 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 348 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 349 AUSTRALIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 AUSTRALIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 353 AUSTRALIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 AUSTRALIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 AUSTRALIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 AUSTRALIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 AUSTRALIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 AUSTRALIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 AUSTRALIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 AUSTRALIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 AUSTRALIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 363 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 364 AUSTRALIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 AUSTRALIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 AUSTRALIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 368 AUSTRALIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 AUSTRALIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 371 AUSTRALIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 AUSTRALIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 374 AUSTRALIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 378 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 380 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 381 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 383 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 384 SINGAPORE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 SINGAPORE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 386 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 388 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 389 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 391 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 392 SINGAPORE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 SINGAPORE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 394 SINGAPORE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 395 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 397 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 398 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 399 SINGAPORE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 SINGAPORE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 403 SINGAPORE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 SINGAPORE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 SINGAPORE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 SINGAPORE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 SINGAPORE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 SINGAPORE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 SINGAPORE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 SINGAPORE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 SINGAPORE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 413 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 414 SINGAPORE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 SINGAPORE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 SINGAPORE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 418 SINGAPORE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 SINGAPORE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 421 SINGAPORE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 SINGAPORE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 424 SINGAPORE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 428 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 430 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 431 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 433 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 434 THAILAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 THAILAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 436 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 438 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 439 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 441 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 442 THAILAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 THAILAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 444 THAILAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 445 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 446 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 447 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 448 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 449 THAILAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 THAILAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 453 THAILAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 THAILAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 THAILAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 THAILAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 THAILAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 THAILAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 THAILAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 THAILAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 THAILAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 463 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 464 THAILAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 THAILAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 THAILAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 468 THAILAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 THAILAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 471 THAILAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 THAILAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 474 THAILAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 478 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 480 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 481 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 483 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 484 INDONESIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 INDONESIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 486 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 488 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 489 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 491 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 492 INDONESIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 INDONESIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 494 INDONESIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 495 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 497 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 498 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 499 INDONESIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 INDONESIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 503 INDONESIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 INDONESIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 INDONESIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 INDONESIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 INDONESIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 INDONESIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 INDONESIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 INDONESIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 INDONESIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 513 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 514 INDONESIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 INDONESIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 516 INDONESIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 518 INDONESIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 INDONESIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 521 INDONESIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 INDONESIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 524 INDONESIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 528 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 530 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 531 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 533 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 534 MALAYSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 MALAYSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 536 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 538 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 539 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 541 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 542 MALAYSIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 MALAYSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 544 MALAYSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 545 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 547 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 548 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 549 MALAYSIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 MALAYSIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 553 MALAYSIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 MALAYSIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 MALAYSIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 MALAYSIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 MALAYSIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 MALAYSIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 MALAYSIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 MALAYSIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 MALAYSIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 562 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 563 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 564 MALAYSIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 MALAYSIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 MALAYSIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 568 MALAYSIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 MALAYSIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 571 MALAYSIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 MALAYSIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 574 MALAYSIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 575 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 578 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 580 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 581 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 582 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 583 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 584 TAIWAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 585 TAIWAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 586 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 588 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 589 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 591 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 592 TAIWAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 TAIWAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 594 TAIWAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 595 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 597 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 598 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 599 TAIWAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 TAIWAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 603 TAIWAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 TAIWAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 TAIWAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 TAIWAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 TAIWAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 TAIWAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 TAIWAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 TAIWAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 TAIWAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 613 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 614 TAIWAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 TAIWAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 TAIWAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 618 TAIWAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 TAIWAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 621 TAIWAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 TAIWAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 624 TAIWAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 627 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 628 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 630 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 631 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 633 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 634 NEW ZEALAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 NEW ZEALAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 636 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 638 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 639 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 641 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 642 NEW ZEALAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 NEW ZEALAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 644 NEW ZEALAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 645 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 647 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 648 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 649 NEW ZEALAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 650 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 651 NEW ZEALAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 652 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 653 NEW ZEALAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 654 NEW ZEALAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 655 NEW ZEALAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 NEW ZEALAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 NEW ZEALAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 NEW ZEALAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 NEW ZEALAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 NEW ZEALAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 NEW ZEALAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 663 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 664 NEW ZEALAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 NEW ZEALAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 NEW ZEALAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 668 NEW ZEALAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 NEW ZEALAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 671 NEW ZEALAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 672 NEW ZEALAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 673 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 674 NEW ZEALAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 677 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 678 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 680 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 681 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 683 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 684 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 686 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 688 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 689 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 690 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 691 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 692 PHILIPPINES INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 PHILIPPINES INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 694 PHILIPPINES INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 695 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 697 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 698 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 699 PHILIPPINES MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 700 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 PHILIPPINES BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 703 PHILIPPINES SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 PHILIPPINES LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 PHILIPPINES ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 PHILIPPINES LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 PHILIPPINES PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 PHILIPPINES CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 PHILIPPINES STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 PHILIPPINES GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 711 PHILIPPINES HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 713 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 714 PHILIPPINES HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 715 PHILIPPINES AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 716 PHILIPPINES GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 717 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 718 PHILIPPINES MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 PHILIPPINES FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 720 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 721 PHILIPPINES HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 PHILIPPINES SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 724 PHILIPPINES RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 728 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 730 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 731 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 733 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 734 VIETNAM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 735 VIETNAM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 736 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 738 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 739 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 741 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 742 VIETNAM INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 743 VIETNAM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 744 VIETNAM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 745 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 747 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 748 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 749 VIETNAM MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 VIETNAM BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 753 VIETNAM SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 VIETNAM LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 VIETNAM ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 VIETNAM LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 VIETNAM PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 758 VIETNAM CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 VIETNAM STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 VIETNAM GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 VIETNAM HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 763 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 764 VIETNAM HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 765 VIETNAM AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 VIETNAM GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 768 VIETNAM MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 VIETNAM FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 771 VIETNAM HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 VIETNAM SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 774 VIETNAM RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 REST OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET IN 2025-2032
FIGURE 13 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE
FIGURE 14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 15 STRATEGIC DECISIONS
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET
FIGURE 17 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 18 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 20 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024
FIGURE 22 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)
FIGURE 24 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024
FIGURE 26 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)
FIGURE 28 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024
FIGURE 30 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 32 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024
FIGURE 34 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024
FIGURE 38 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 39 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 40 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 42 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
